Announcements Trials
Browse Landscape

Phase

Phase 3 5

Status

Completed 16Recruiting 5Terminated 3No longer available 3Active not recruiting 3Withdrawn 1

Sponsor Class

INDUSTRY 5OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5

Conditions

Multiple Myeloma 5Neoplasms, Plasma Cell 1

Interventions

pembrolizumab 241Carboplatin 167Injections 138Paclitaxel 119Gemcitabine 116Bevacizumab 112Cisplatin 105Docetaxel 82Cyclophosphamide 78Pemetrexed 76Capecitabine 69Fluorouracil 67Oxaliplatin 65Fulvestrant 57fludarabine 55Nivolumab 55Leucovorin 52Cetuximab 52130-nm albumin-bound paclitaxel 47Dexamethasone 46Rituximab 41atezolizumab 37venetoclax 35Drug Therapy 35toripalimab 34enzalutamide 34Irinotecan 34durvalumab 32Prednisone 32Letrozole 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × elotuzumab × Clear all
NCT06152575 2026-06-05

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Pfizer

Phase 3 Recruiting
492 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06158841 2026-06-05

CERVINO

AbbVie

Phase 3 Recruiting
380 enrolled
Plasma cell

Multiple Myeloma

NCT06208150 2026-06-05

MonumenTAL-6

Janssen Research & Development, LLC

Phase 3 Recruiting
795 enrolled
Plasma cell

Multiple Myeloma

NCT07555938 2026-05-27

CEVOLUTION

Hoffmann-La Roche

Phase 3 Recruiting
380 enrolled
Plasma cell

Multiple Myeloma

NCT05730036 2026-03-06

LINKER-MM3

Regeneron Pharmaceuticals

Phase 3 Recruiting
410 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡